BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.

Bernadetta Płatkowska-Adamska, Agnieszka Bociek, Magdalena Kal, Dorota Zarębska-Michaluk, Dominik Odrobina
{"title":"BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy.","authors":"Bernadetta Płatkowska-Adamska, Agnieszka Bociek, Magdalena Kal, Dorota Zarębska-Michaluk, Dominik Odrobina","doi":"10.23736/S0026-4806.24.09379-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Due to safety concerns, patients were hesitant to receive a booster dose of COVID-19 vaccine. In this study, we investigated whether neovascular age-related macular degeneration activity deteriorated after receiving the booster dose of the BNT162b2 vaccine.</p><p><strong>Methods: </strong>Optical coherence tomography (OCT) of the macula, best-corrected visual acuity (BCVA), and slit-lamp examination data were collected from 89 patients. All these individuals were diagnosed with neovascular age-related macular degeneration (AMD) and treated with intravitreal injections of aflibercept or ranibizumab. During the process of treatment, patients received a booster dose of the BNT162b2 vaccine. Time points included two visits before (marked as \"-2\", \"-1\") and two visits after (marked as \"1\", \"2\") the uptake of the booster dose.</p><p><strong>Results: </strong>There were significant differences in the average thickness and total volume of the macula during follow-up. Moreover, a decreased average thickness, total volume, total thickness of the macula, subretinal fluid thickness, and subretinal complex thickness was observed between the time points \"-2\" and \"2\", but only in the aflibercept group. There were no significant differences in the frequency of occurring intraretinal cysts, subretinal fluid, serous retinal pigment epithelial detachments retinal hemorrhage, subretinal hyperreflective material, complete RPE and outer retinal atrophy, and BCVA before and after the booster dose.</p><p><strong>Conclusions: </strong>These results demonstrate that the BNT162b2 vaccine booster dose did not deteriorate the course of neovascular AMD.</p>","PeriodicalId":94143,"journal":{"name":"Minerva medica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva medica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0026-4806.24.09379-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Due to safety concerns, patients were hesitant to receive a booster dose of COVID-19 vaccine. In this study, we investigated whether neovascular age-related macular degeneration activity deteriorated after receiving the booster dose of the BNT162b2 vaccine.

Methods: Optical coherence tomography (OCT) of the macula, best-corrected visual acuity (BCVA), and slit-lamp examination data were collected from 89 patients. All these individuals were diagnosed with neovascular age-related macular degeneration (AMD) and treated with intravitreal injections of aflibercept or ranibizumab. During the process of treatment, patients received a booster dose of the BNT162b2 vaccine. Time points included two visits before (marked as "-2", "-1") and two visits after (marked as "1", "2") the uptake of the booster dose.

Results: There were significant differences in the average thickness and total volume of the macula during follow-up. Moreover, a decreased average thickness, total volume, total thickness of the macula, subretinal fluid thickness, and subretinal complex thickness was observed between the time points "-2" and "2", but only in the aflibercept group. There were no significant differences in the frequency of occurring intraretinal cysts, subretinal fluid, serous retinal pigment epithelial detachments retinal hemorrhage, subretinal hyperreflective material, complete RPE and outer retinal atrophy, and BCVA before and after the booster dose.

Conclusions: These results demonstrate that the BNT162b2 vaccine booster dose did not deteriorate the course of neovascular AMD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在抗血管内皮生长因子治疗期间,BNT162b2 疫苗加强剂量不会影响老年性黄斑变性渗出型的活性。
背景:出于安全考虑,患者对接种COVID-19疫苗的加强剂量犹豫不决。在这项研究中,我们调查了接受 BNT162b2 疫苗加强剂量后新生血管性老年黄斑变性的活动是否会恶化:收集了 89 名患者的黄斑光学相干断层扫描(OCT)、最佳矫正视力(BCVA)和裂隙灯检查数据。所有这些患者均被诊断为新生血管性老年黄斑变性(AMD),并接受了阿弗利百普或雷尼珠单抗的玻璃体内注射治疗。在治疗过程中,患者接种了一剂BNT162b2疫苗。时间点包括接种加强剂量前(标记为"-2"、"-1")和接种加强剂量后(标记为 "1"、"2")的两次就诊:结果:随访期间,黄斑的平均厚度和总体积有明显差异。此外,在"-2 "和 "2 "时间点之间,观察到平均厚度、总体积、黄斑总厚度、视网膜下积液厚度和视网膜下复合体厚度均有所下降,但仅阿夫利拜因组有所下降。加强剂量前后,视网膜内囊肿、视网膜下积液、浆液性视网膜色素上皮脱落视网膜出血、视网膜下高反光物质、RPE和外层视网膜完全萎缩以及BCVA的发生频率无明显差异:这些结果表明,BNT162b2疫苗加强剂量不会恶化新生血管性AMD的病程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effects of dual-sufficiency modified nursing care on treatment compliance and adverse cardiovascular events in elderly patients with coronary heart disease after interventional surgery. A systematic review and meta-analysis of the clinical efficacy of different vertebroplasties in the treatment of osteoporotic spinal fractures in the elderly. Detection method of inflammatory cells in cytopathological images of chronic rhinosinusitis. BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy. Identification of biomarkers and construction of a clinical-radiomics model for predicting functional outcome in acute ischemic stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1